

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: May 9, 2011  
(Date of earliest event reported)

**NOVELOS THERAPEUTICS, INC.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

---

**333-119366**  
(Commission  
File Number)

---

**04-3321804**  
(IRS Employer  
Identification Number)

**One Gateway Center, Suite 504**  
**Newton, MA 02458**  
(Address of principal executive offices)

**(617) 244-1616**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 7.01 REGULATION FD DISCLOSURE**

On May 9, 2011, we issued a press release announcing that our trading symbol has reverted to NVLT following a twenty day post-split trading period. A copy of the press is furnished as Exhibit 99.1 and is incorporated by reference in this Item.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

**c) Exhibits**

Number	Title
99.1	Press Release dated May 9, 2011 entitled "Novelos Therapeutics Trading Symbol Reverts to NVLT"

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 9, 2011

NOVELOS THERAPEUTICS, INC.

By: /s/ Harry S. Palmin  
Harry S. Palmin  
President and Chief Executive Officer

## EXHIBIT INDEX

Number	Title
99.1	Press Release dated May 9, 2011 entitled "Novelos Therapeutics Trading Symbol Reverts to NVLT"

**NOVELOS THERAPEUTICS TRADING SYMBOL REVERTS TO NVLT**

**MADISON, WI, May 9, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT)**, a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, announced that today its trading symbol has reverted to NVLT. The twenty day post-split trading period has ended.

**About Novelos Therapeutics, Inc.**

We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. We currently have three cancer-targeted compounds, which are selectively taken up and retained in cancer cells (including cancer stem cells) versus normal cells. Thus, our therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy – efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. LIGHT is a small-molecule cancer imaging agent. We believe LIGHT has first-in-class potential and expect it to enter Phase 1/2 clinical trials middle of this year. HOT is a small-molecule, broad-spectrum, cancer-targeted radiopharmaceutical that delivers radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-in-class potential, and we expect it to enter a Phase 1b dose escalation trial in the third quarter of this year and Phase 2 trials in mid-2012 as a monotherapy for solid tumors with significant unmet medical need. COLD, a cancer-targeted chemotherapy that we expect to enter clinical trials late in 2012, works primarily through Akt inhibition. Together, we believe our compounds are able to “find, treat and follow” cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit [www.novelos.com](http://www.novelos.com)

**COMPANY**

Harry S. Palmin, President and CEO  
Ph: 617-244-1616 x11  
Email: [hpalmin@novelos.com](mailto:hpalmin@novelos.com)

**INVESTOR RELATIONS**

Patrick Genn, Exec. Director  
Ph: 858-775-7456  
Email: [pgenn@novelos.com](mailto:pgenn@novelos.com)

Novelos Therapeutics, Inc.  
Madison, WI                      Boston, MA

This news release contains forward-looking statements. You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.

###

---